Want to see GLUE full AI Analyst Report?
GLUE Stock Chart & Stats
$14.38
$0.07(0.31%)
At close: 4:00 PM EDT
$14.38
$0.07(0.31%)
Day’s Range― - ―
52-Week Range$4.78 - $25.77
Previous CloseN/A
Volume570.68K
Average Volume (3M)1.36M
Market Cap
$1.22B
Enterprise Value$1.87K
Total Cash (Recent Filing)$621.10M
Total Debt (Recent Filing)$37.99M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 05, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding85,313,400
10 Day Avg. Volume1,102,605
30 Day Avg. Volume1,360,547
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)4.41
Price to Sales (P/S)8.31
P/FCF Ratio-37.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.83Price Target Upside100.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$44.46M
Bulls Say, Bears Say
Bulls Say
Conservative LeverageLow debt relative to equity provides financial flexibility for continued research and development. This reduces near-term balance-sheet pressure and gives the company more capacity to fund its platform while pursuing collaboration or financing opportunities.
High Gross MarginThe very high reported gross margin indicates potentially attractive economics on collaboration-related revenue and future products. If sustained as programs advance, this could support meaningful operating leverage once development spending and commercial scale improve.
Improving Cash-Burn DynamicsAlthough cash flow remains negative, improving free cash flow and a smaller cash loss than accounting net loss suggest some progress in burn management. Sustained improvement could extend funding runway and reduce dependence on external capital.
Bears Say
Declining RevenueThe sharp revenue decline signals volatility in collaboration and licensing receipts and weakens visibility into the business model. Continued contraction could limit internal funding for clinical programs and increase reliance on new partnerships or financing.
Deep Net LossesLarge ongoing losses show that the current revenue base does not cover research, development, and operating costs. If losses persist, they can erode the equity base, constrain strategic flexibility, and require repeated access to external funding.
Continued Cash BurnNegative operating and free cash flow means the company is not yet self-funding its development activities. Persistent burn increases dependence on collaboration receipts, equity issuance, or other financing to maintain clinical and platform investment.
Monte Rosa Therapeutics News
GLUE FAQ
What was Monte Rosa Therapeutics’s price range in the past 12 months?
Monte Rosa Therapeutics lowest stock price was $4.78 and its highest was $25.77 in the past 12 months.
What is Monte Rosa Therapeutics’s market cap?
Monte Rosa Therapeutics’s market cap is $1.22B.
When is Monte Rosa Therapeutics’s upcoming earnings report date?
Monte Rosa Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 62 days.
How were Monte Rosa Therapeutics’s earnings last quarter?
Monte Rosa Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.38 by -$0.05.
Is Monte Rosa Therapeutics overvalued?
According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued.
Does Monte Rosa Therapeutics pay dividends?
Monte Rosa Therapeutics does not currently pay dividends.
What is Monte Rosa Therapeutics’s EPS estimate?
Monte Rosa Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Monte Rosa Therapeutics have?
Monte Rosa Therapeutics has 85,313,400 shares outstanding.
What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?
Monte Rosa Therapeutics reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.38. Following the earnings report the stock price went up 0.641%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics?
Currently, no hedge funds are holding shares in GLUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monte Rosa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.83 (100.51% Upside)
$28.83 (100.51% Upside)
Blogger Sentiment
Bullish
GLUE Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $451.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 9.5%
Last 30 Days ▼ 9.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
189.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
92.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
GLUE Stock 12 Month Forecast
Average Price Target
$28.83
▲(100.51% Upside)
Technical Analysis
CytomX Therapeutics
―
Fulcrum Therapeutics
―
Monopar Therapeutics Inc
―
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.88% Insiders
14.97% Mutual Funds
58.66% Other Institutional Investors
1.43% Public Companies and
Individual Investors